CLOSURE-AF Trial Results: LAA Closure vs. Medical Therapy in High Bleeding Risk AF
The results of the pragmatic randomized CLOSURE-AF trial are now available.
Fresh materials — Medical news
ORBITA-CTO: PCI vs. Placebo in Chronic Total Occlusion Treatment
This study, with its results presented at the ACC.26 conference, marks the first randomized, placebo-controlled trial ever conducted for this specific procedure, a context where maintaining blinding is notably challenging.
The SMART-DECISION Study: Discontinuation of Beta-Blockers After Myocardial Infarction
The SMART-DECISION study, a significant research initiative conducted in South Korea, investigated the feasibility of discontinuing beta-blocker therapy in a specific patient population. Specifically, the research focused on individuals who had experienced a myocardial infarction (heart attack)
Scout-HCM: Mavacamten Effectively Reduces LVOT Obstruction in Adolescents with HCM
The significant findings from the Scout-HCM study reveal the efficacy of mavacamten in addressing left ventricular outflow tract obstruction in adolescent patients with hypertrophic cardiomyopathy.
Spironolactone in Elderly Patients with HFpEF/HFmrEF: The SPIRIT-HF Study Suggests Caution
This research, presented at ACC.26, investigated the efficacy of spironolactone compared to placebo in an elderly patient population diagnosed with heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction.
Lower LDL Cholesterol, Fewer Events: The Ez-PAVE Trial Validates Target Levels
The pivotal research study was presented at the annual meeting of the American College of Cardiology (ACC.26) and concurrently published in the esteemed New England Journal of Medicine.
Exploring the Link Between Screen Time and Cardiovascular Risk
A forthcoming study, scheduled for presentation at ACC.26, has investigated the association between hours spent in front of screens, physical activity levels, and key markers of cardiovascular risk.